Stockscreener 앱 받기
20.10
0.54%
-0.11
시간 외 거래:
20.10
전일 마감가:
$20.21
열려 있는:
$20.26
하루 거래량:
786.72K
Relative Volume:
0.97
시가총액:
$940.86M
수익:
$82.71M
순이익/손실:
$-102.24M
주가수익비율:
-5.4768
EPS:
-3.67
순현금흐름:
$-76.57M
1주 성능:
-5.85%
1개월 성능:
+1.36%
6개월 성능:
-0.05%
1년 성능:
+90.70%
1일 변동 폭
$19.95
$21.62
1주일 범위
$19.65
$22.25
52주 변동 폭
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
명칭
Urogen Pharma Ltd
전화
972 9 770 7601
주소
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
20.10 | 946.01M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-06-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-19 | 재개 | Ladenburg Thalmann | Buy |
| 2024-08-22 | 개시 | Guggenheim | Buy |
| 2023-02-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-27 | 개시 | Berenberg | Buy |
| 2020-04-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-13 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | National Securities | Neutral |
| 2019-05-30 | 개시 | JP Morgan | Neutral |
| 2019-05-29 | 개시 | Goldman | Neutral |
| 2019-01-29 | 개시 | H.C. Wainwright | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-04-04 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-11-15 | 재확인 | Oppenheimer | Outperform |
| 2017-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
Shorts Report: What is UroGen Pharma Ltd. s P E ratio telling usCPI Data & Verified Momentum Stock Alerts - mfd.ru
Big Picture: Is UroGen Pharma Ltd. stock a top momentum playJuly 2025 Trends & Expert Approved Trade Ideas - mfd.ru
UroGen Pharma at Guggenheim Summit: Strategic Advances in Biotech By Investing.com - Investing.com South Africa
UroGen Pharma Ltd. (URGN) Investor Outlook: Exploring A 66.75% Potential Upside - DirectorsTalk Interviews
Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 7,479 Shares - MarketBeat
Market Sentiment Around Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st
(URGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
UroGen Pharma Ltd. (URGN) Stock Analysis: Unveiling a 70% Upside Potential in Biotechnology - DirectorsTalk Interviews
UroGen Pharma CMO Schoenberg sells $145k in shares - Investing.com
UroGen Pharma CMO Schoenberg sells $145k in shares By Investing.com - Investing.com South Africa
Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 7,373 Shares - MarketBeat
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit - Caledonian Record
Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Privium Fund Management B.V. Increases Stock Position in Urogen Pharma $URGN - MarketBeat
Update Recap: Is now the right time to enter UroGen Pharma LtdWeekly Risk Report & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Bull Run: Can UroGen Pharma Ltd deliver consistent dividendsJuly 2025 Spike Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Responsive Playbooks and the URGN Inflection - Stock Traders Daily
Dividend Watch: Is now the right time to enter UroGen Pharma LtdJuly 2025 Setups & Growth Oriented Trading Recommendations - baoquankhu1.vn
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA - GuruFocus
URGN: Analyst Jason Kolbert Maintains 'Buy' Rating with $33 Pric - GuruFocus
Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
UroGen Pharma Ltd. (URGN) Stock Analysis: Investors Eye 83% Upside Amid Biotech Innovations - DirectorsTalk Interviews
Harel Insurance Investments & Financial Services Ltd. Trims Holdings in Urogen Pharma $URGN - MarketBeat
UroGen drops 20% as FDA releases docs in advance of AdCom meeting - MSN
JELMYTO shows promise in long-term cancer treatment study - MSN
Piper Sandler Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $40 - 富途牛牛
Understanding the Setup: (URGN) and Scalable Risk - Stock Traders Daily
Technical Analysis: Is UroGen Pharma Ltd stock affected by interest rate hikesWeekly Trade Report & Weekly Top Stock Performers List - Bộ Nội Vụ
Urogen Pharma (NASDAQ:URGN) Stock Price Down 6.7%Here's What Happened - MarketBeat
Aug Shorts: How interest rate cuts could boost UroGen Pharma Ltd stockQuarterly Portfolio Report & Technical Pattern Based Signals - Bộ Nội Vụ
Momentum Shift: How interest rate cuts could boost UroGen Pharma Ltd stock2025 Performance Recap & Risk Controlled Daily Trade Plans - Bộ Nội Vụ
Assessing UroGen Pharma (URGN) Valuation After ZUSDURI Secures Permanent J Code - simplywall.st
Is UroGen Pharma Ltd stock ready for breakoutMarket Weekly Review & Accurate Buy Signal Notifications - Bộ Nội Vụ
Block Trades: Will UroGen Pharma Ltd stock benefit from infrastructure spending2025 Short Interest & Step-by-Step Swing Trade Plans - Bộ Nội Vụ
Why UroGen Pharma Ltd. stock appeals to analystsQuarterly Market Summary & Safe Entry Zone Identification - Улправда
Urogen Pharma (NASDAQ:URGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Will UroGen Pharma Ltd. stock benefit from infrastructure spendingChart Signals & Verified Swing Trading Watchlists - Улправда
Why UroGen Pharma Ltd. (UR8) stock attracts HNW investorsJuly 2025 Short Interest & Reliable Trade Execution Plans - ulpravda.ru
Is UroGen Pharma Ltd. stock oversold or undervalued2025 Market Outlook & High Win Rate Trade Tips - Улправда
What momentum indicators show for UroGen Pharma Ltd. stock2025 Key Highlights & Advanced Technical Analysis Signals - Улправда
Will UroGen Pharma Ltd. stock see insider buyingFundamental Strength Indicators & Free Unlock Rapid Growth Potential - Улправда
UroGen Pharma Ltd. (URGN) Stock Analysis: A Biotechnology Innovator with Over 52% Potential Upside - DirectorsTalk Interviews
Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors - simplywall.st
How UroGen Pharma Ltd. (UR8) stock trades in high volatility2026 world cup usa national team round of 32 playmakers possession football expert forecast preview - Улправда
UroGen Pharma says permanent J Code for ZUSDURI now in effect - Yahoo Finance
Urogen Pharma (NASDAQ:URGN) Shares Down 6.5%What's Next? - MarketBeat
UroGen Pharma Ltd. Announces That Adult Patients Living with Recurrent Low-Grade Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) Now Have Improved Access to an Important Therapy - marketscreener.com
UroGen Pharma (URGN) Analyst Ratings Remain Steady with Buy Rati - GuruFocus
D. Boral Capital Reiterates "Buy" Rating for Urogen Pharma (NASDAQ:URGN) - MarketBeat
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy - GlobeNewswire
Urogen Pharma Ltd (URGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Urogen Pharma Ltd 주식 (URGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schoenberg Mark | Chief Medical Officer |
Feb 03 '26 |
Sale |
19.69 |
7,373 |
145,174 |
144,985 |
1.12%
0.87%
자본화:
|
볼륨(24시간):